Fibrosis and Aging
Approximately 45% of mortality in Western nations is attributed to fibrotic diseases, characterized by formation of excess fibrous connective tissue in an organ or tissue. Fibrotic diseases encompass organ-specific diseases, such as cardiac fibrosis, idiopathic pulmonary fibrosis, intestinal fibrosis, liver fibrosis and cirrhosis, and multisystem disorders, such as systemic sclerosis, nephrogenic systemic fibrosis, and chronic graft versus host disease. Fibrosis is also observed in the stromal response to many solid tumors. Additionally, fibrosis is one of the key features of vascular remodeling in atherosclerosis and of airway remodeling in patients with asthma [1] .
Fibrosis typically develops in response to initial inflammatory processes and the major causes are tissue damage, infection, and autoimmune disease [2] . Aging is considered a risk factor for fibrosis and the incidence increases sharply with advancing age for many fibrosis-associated diseases, e.g. cardiovascular disease and arteriosclerosis, hepatic fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, and benign prostatic hyperplasia [3] . The molecular mechanisms underlying these age-related differences in disease incidence are not well understood. However, several age-related factors have been proposed, including accumulation of cellular or molecular damage, impaired stress response, cellular senescence, dysregulation of telomere biology, loss of proteostasis, and epigenetic alterations [3, 4] .
Aging is accompanied by increased oxidative stress and accumulation of advanced glycation end products (AGEs) that have both been associated with development of fibrosis suggesting a direct link between oxidative stress and fibrosis in the course of aging [5, 6] . Furthermore, it has been shown in rat renal fibroblasts that AGEs decreased nitric oxide (NO) production and reduced protein kinase G (PKG) activity and thus reduced NO/ cyclic guanosine monophosphate (cGMP) signaling that is also decreased in fibrotic remodeling [1, 3, 6] . In consequence to aging, stromal prostate cells secrete elevated levels of inflammatory mediators such as secreted CXC-type chemokines that promote increases in the proliferation rate of epithelial and stromal cells, a hallmark of fibrotic alterations in benign prostatic hyperplasia [7] . It has been demonstrated that cGMP increase is able to attenuate inflammatory response in human prostatic myofibroblasts, suggesting a link between impairment of the NO/cGMP and inflammation-dependent fibrosis [8] . Moreover, in aging mice, decreased Thy-1 expression in pulmonary fibroblasts was observed, which resulted in the production of a profibrotic extracellular matrix (ECM) [9] . While the severity of fibrosis in response to lung injury is not significantly different in young and aged mice, the latter demonstrate an impaired capacity for fibrosis resolution resulting in persistent fibrosis characterized by the accumulation of senescent and apoptosis-resistant myofibroblasts [10, 11] .
The Myofibroblast: The Primary Effector Cell in Fibrosis
Myofibroblasts are the primary effector cells in fibrosis. They are a specialized cell type that combines the ECM-producing characteristics of fibroblasts with the cytoskeletal and contractile properties of smooth muscle cells [12] . Various cell types have been described and discussed as potential precursor cells of myofibroblasts including local epithelial cells, endothelial cells, smooth muscle cells, pericytes, mesenchymal stem cells, and bone marrow-derived fibrocytes. However, it appears likely that local fibroblasts represent the major source of myofibroblasts [12] . ECM stiffness in conjunction with transforming growth factor-β 1 (TGFβ1) represents a primary stimulus for myofibroblast differentiation and persistence in response to tissue damage or chronic inflammation. The differentiated myofibroblasts produce and deposit new ECM components and secrete a variety of growth factors and cytokines, resulting in enhanced proliferation of the remaining fibroblasts. Moreover, myofibroblasts also secrete and activate TGFβ1, thereby generating an autocrine feed-forward loop that further drives myofibroblast differentiation [3, 12] .
Molecular Pathways Underlying Myofibroblast Activation and Fibrogenesis
Soluble factors and cytokines secreted by platelets and infiltrating leukocytes, such as interleukins, tumor necrosis factor, TGFβ, and platelet-derived growth factor (PDGF), play major roles in fibrogenesis. The molecular pathways and complex interplay between initial inflammation, inflammatory cytokines, TGFβ1, and other growth factors, including PDGF, fibroblast growth factor (FGF), and locally produced cytokines, are not yet fully understood. These mechanisms and relationships may also be age and tissue dependent, and need further investigation. This has led to current treatment approaches that are quite diverse and high failure rates for experi-mental medicines in clinical trials. However, there are some common pathways that are central and conserved within age-dependent fibrotic remodeling, such as the above-mentioned myofibroblast differentiation.
The Role of TGFβ in Fibrosis
TGFβ is widely considered the most important profibrotic growth factor and undoubtedly plays a pivotal role in pathogenic fibrogenesis. Consistently, elevated levels of TGFβ and enhanced TGFβ signaling have been observed in various fibrotic disorders including renal interstitial fibrosis, idiopathic pulmonary fibrosis, cardiovascular remodeling, chronic liver disease, systemic sclerosis, benign prostatic hyperplasia and tumor-associated reactive stroma [1, 3, 13] . At a cellular level, the profibrotic effects of TGFβ are mediated via downstream activation of canonical Smad2/3 signaling or via noncanonical Smad-independent activation of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/Akt pathways and result in production and deposition of ECM and secretion of paracrine-and autocrine-acting growth factors, further modulating cellular signaling cascades [1] .
TGFβ1-induced myofibroblast differentiation and myofibroblast-driven formation of ECM components is caused by a pro-oxidant shift in redox homeostasis. The underlying mechanism involves elevation of nicotinamide adenine dinucleotide phosphate oxidase 4-derived hydrogen peroxide and concomitant decreases in reactive oxygen species-scavenging enzymes such as manganesedependent superoxide dismutase (SOD) or the Se-containing enzymes glutathione peroxidase 3 (GPX3) and thioredoxin reductase 1 (TXNRD1) [1, 3, 14] . Of note, fibroblasts from aged mice displayed an impaired capacity to induce the antioxidant response of NFE2-related factor 2, a master regulator of antioxidant genes, following lung injury [10] . The resulting pro-oxidant shift in redox homeostasis leads to NO synthase (NOS) uncoupling and a concomitant decrease in NO signaling and PKG activity [1, 3] . The first messenger NO triggers the formation of cGMP, which acts as a second messenger and mediates the NO-related effects. Therefore, enhancement of NO/cGMP signaling may target a common pathway in the development of fibrosis and could represent a potential therapeutic strategy to target myofibroblast differentiation in fibrotic diseases. Recently, agents from a specific class of compounds, the so-called soluble guanylate cyclase (sGC) modulators, were approved for cardiopulmonary diseases, and others are in clinical development for cardiovascular indications [15] [16] [17] [18] . This class of compounds binds selectively to sGC, thereby stimulating sGC activity, which causes a significant increase in cGMP levels. As these compounds are effective independent of NO, this could be of importance in fibrotic diseases where endogenous NO production is low. This review summarizes the preclinical evidence for antifibrotic effects of sGC modulators in vitro and in animal models. One of the most important pathways regulating vascular tone and leading to vasorelaxation is the NO/cGMP/ phosphodiesterase type 5 (PDE5) pathway. This pathway and its pharmacological modulation have been extensively reviewed in the literature and covered in depth in the Handbook of Experimental Pharmacology [19] . In brief, NO is formed from L -arginine via the activity of NOSs, of which three isozymes have been identified to date: endothelial NOS (eNOS), neuronal NOS, and an inducible form of NOS. In the first step of the pathway, NO formed via NOS is liberated by nerve fibers or endothelial cells and then binds to sGC, which triggers enhanced cGMP formation. In the next step, cGMP regulates the activity of various downstream targets, mainly cGMP-regulated protein kinases (e.g. PKG), cGMP-regulated PDEs, and cGMP-regulated ion channels. These cGMP downstream targets translate the increase in cGMP levels into a decrease in intracellular free calcium levels in smooth muscle cells. Thus, one of the most prominent physiological responses of increasing intracellular cGMP levels, especially in smooth muscle cells, is relaxation of smooth muscle cells. The relaxing effects of cGMP are abrogated by cleavage of cGMP through highly effective PDEs, in particular PDE5 ( fig. 1 ) [19] .
Pharmacological cGMP Increase: Modulating sGC Activity
As the NO/cGMP/PDE5 signaling cascade is of paramount importance for regulation of vascular tone, even before the signal transduction pathway was fully understood, pharmaceuticals were introduced that enhanced vasorelaxation, aiming to improve local blood flow and oxygen supply in tissues [19] . The first pharmacological interventions in this pathway were nitrates and NO donors, which mimic the action of NO, for the treatment of angina pectoris as these compounds effectively dilate coronary blood vessels. More recently, PDE5 inhibitors were introduced for the treatment of erectile dysfunction. Some of these compounds were subsequently approved for the treatment of pulmonary arterial hypertension (PAH) and for signs and symptoms of benign prostatic hyperplasia [19] .
The most recently introduced class of compounds to effectively target this pathway are modulators of the sGC, the sGC stimulators and sGC activators, which both stimulate sGC independently from NO to trigger increases in cGMP levels. The discovery of these compounds in the late 1990s was a milestone in overcoming the treatment limitations of nitrates and PDE5 inhibitors. Initially, these compounds were termed sGC stimulators and/or sGC activators or compounds stimulating and/or activating sGC, irrespective of their distinct properties with respect to binding to sGC, i.e. heme-containing or hemefree forms of the enzyme. In recent years, two classes of compounds have been defined: sGC stimulators [20] and sGC activators [21] . [22, 23] . Riociguat was approved in 2013 for the treatment of PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and is marketed as Adempas ® . Owing to their biochemical properties, these compounds are now termed NO-independent heme-dependent sGC stimulators. They stimulate sGC independently from NO but also act synergistically with NO and are able to substantially enhance the effects of very low levels of endogenous NO. 
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sGC Activators
More recently, another group of compounds was developed that activates sGC independently from NO and does not require the heme group of the enzyme. Thus, these compounds have been termed NO-independent heme-independent sGC activators. This group of compounds includes BAY 58-2667 (cinaciguat) and BAY 60-2770 from Bayer, and S-3448 and HMR-1766 (ataciguat) from former Hoechst-Marion Roussel (now Sanofi Aventis) ( fig. 3 ) [22, 23] . The efficacy of sGC activators is independent from bioavailable NO. Additionally, sGC activators show an additive effect with endogenous NO.
Therapeutic Potential of sGC Stimulators and sGC Activators in Fibrotic Diseases
Given the broad impact of the NO/cGMP/PDE5 signaling cascade in health and disease, sGC stimulators and activators exhibit broad treatment potential, particularly in the cardiovascular, cardiopulmonary, and cardiorenal systems. This is indicated by the approval of the sGC stimulator riociguat for PAH and CTEPH, but also by the ongoing clinical development of the sGC stimulator vericiguat (BAY 1021189) in heart failure [18, 24] and research and development efforts with sGC stimulators and activators in chronic kidney diseases [25] . This already demonstrates that the beneficial effects of sGC 'modulators' are much broader than vasodilation alone, which is corroborated by the preclinical literature [15, 26] . It has been shown that increased cGMP levels from sGC stimulators and sGC activators lead to antifibrotic and antiremodeling effects. In addition, antiproliferative, proapoptotic, and anti-inflammatory effects have been demonstrated influencing epithelial function, angiogenesis, adipocyte differentiation and neuroprotection [15, 25, 26] . These properties render sGC modulators promising treatment options for fibrotic disorders, especially in the aging population. Clinical trials are already underway to assess the clinical benefit of sGC stimulators, e.g. in patients with skin fibrosis and systemic sclerosis (NCT02283762). Chemical structures of NO-independent and heme-dependent sGC stimulators that act synergistically with endogenous NO (see [22, 23] 
Antifibrotic Effects of sGC Modulators
Attenuation of ECM Production in Kidney and Heart Fibrosis Fibrotic diseases are characterized by excessive accumulation of ECM [1] . Collagens represent the main structural proteins of ECM, and collagen content can be determined by histological visualization of collagen fibers by Sirius Red staining, immunostaining, or by detection of the collagen-specific amino acid hydroxyproline [27] [28] [29] . Additional markers that have been used to determine ECM accumulation in in vitro and in vivo preclinical studies include the ECM protein fibronectin (FN), expression of protease inhibitors that decrease matrix protein degradation, such as plasminogen activator inhibitor type 1 (PAI-1) and tissue inhibitors of matrix metalloproteinases (TIMPs), and matricellular proteins, such as osteopontin [28, 30] .
The potential of sGC modulators to attenuate ECM accumulation has been studied in various models of fibrotic kidney diseases. In a rat model of acute anti-Thy1-induced mesangial proliferative glomerulonephritis that is characterized by intense ECM accumulation, treatment with the sGC stimulator BAY 41-2272 significantly reduced glomerular matrix accumulation, as determined by immunostaining for collagen IV and FN, compared with placebo on day 6 after disease induction [28] . In a model of chronic glomerulosclerosis that progresses autonomously from anti-Thy1-induced glomerulonephritis in uninephrectomized rats, BAY 41-2272 treatment significantly reduced ECM accumulation determined by histological examination 16 weeks after disease induction (after 15 weeks of treatment). Moreover, mRNA and protein expression of TGFβ1, FN, and PAI-1 in tubulointerstitial tissue and protein expression of TGFβ1 and FN in glomerular tissue were significantly reduced by BAY 41-2272 treatment [31] . The sGC stimulator BAY 41-8543 enhanced renal recovery after relief of unilateral ureteral obstruction in a rat model, as determined by reduced matrix protein expansion, collagen IV deposition, Chemical structures of NO-independent and heme-independent sGC activators (see [22, 23] and reduced mRNA expression of TGFβ1, FN, and PAI-1 [32] .
The sGC activator cinaciguat exerted antifibrotic effects in a rat model of chronic kidney disease. Cinaciguat decreased glomerulosclerosis and renal perivascular and interstitial fibrosis, as determined by Sirius Red staining, but had no significant effect on cardiac fibrosis [33] . Likewise, the sGC stimulator riociguat reduced renal but not cardiac interstitial fibrosis in rats, but in contrast to cinaciguat, riociguat treatment did not affect glomerulosclerosis [34] . BAY 41-8543 treatment did not influence glomerulosclerosis or renal interstitial fibrosis but significantly attenuated uremic aortic remodeling involving reduced collagen I deposition and TIMP-1 gene expression [29] .
In a high-renin model using hypertensive renin transgenic rats treated with the NOS inhibitor N G -nitro-L -arginine methyl ester (L-NAME), riociguat significantly reduced glomerulosclerosis as well as renal and cardiac interstitial fibrosis, as determined by Sirius Red staining [34] . Consistently, riociguat significantly ameliorated glomerulosclerosis, renal and cardiac interstitial fibrosis, and renal but not cardiac perivascular fibrosis following salt-induced hypertension in salt-sensitive Dahl rats. In this animal model, riociguat additionally attenuated the increase in osteopontin, TIMP-1, and PAI-1 mRNA expression in the left ventricle and renal cortex, as well as urinary osteopontin, TIMP-1, and PAI-1 protein levels [30] . BAY 41-2272 significantly decreased interstitial and perivascular collagen accumulation, and TGFβ1 and type 1 collagen gene expression in the left ventricle in rats with hypertension induced by suprarenal aortic constriction [35] . In rats with severe angioproliferative PAH induced by hypoxia and the vascular endothelial growth factor antagonist SU5416, riociguat decreased collagen accumulation in the right ventricle [36] . Treatment with the sGC activator ataciguat reduced interstitial ECM accumulation in the noninfarcted left ventricle of rats with chronic heart failure after myocardial infarction, as determined by hydroxyproline content and Sirius Red staining. Moreover, ataciguat inhibited the induction of collagen expression in cardiac fibroblasts isolated from mice with heart failure and in primary human cardiac fibroblasts [27] .
Attenuation of ECM Production in Liver, Peritoneal and Skin Fibrosis
Besides kidney and heart diseases, sGC modulators have demonstrated antifibrotic effects in other tissues. The sGC activator BAY 60-2770 attenuated liver fibrosis as determined by total hydroxyproline content and Sirius Red staining in two rat models, the pig serum model, and the carbon tetrachloride model [37] . Furthermore, BAY 60-2770 treatment prevented progression and accelerated regression of thioacetamide-induced hepatic fibrosis in rats [38] . In an experimental model of peritoneal fibrosis induced by peritoneal injury in eNOS-deficient mice, treatment with BAY 41-2272 reduced ECM accumulation, as determined by type 1 collagen gene expression [39] .
Treatment with BAY 41-2272 dose-dependently prevented development and induced regression of fibrosis, as determined by attenuated dermal thickening and ECM accumulation measured as dermal hydroxyproline content, in a mouse model of dermal fibrosis induced by intradermal injection of bleomycin and in the tight skin 1 mouse model [40] . Moreover, BAY 41-2272 attenuated dermal thickening and hydroxyproline content in a mouse model of dermal fibrosis induced by overexpression of constitutively active TGFβ receptor 1 and dosedependently reduced TGFβ1-induced type 1 collagen gene expression and total collagen content in human primary fibroblasts isolated from healthy individuals or patients with systemic sclerosis [40, 41] . Similarly, riociguat dose-dependently reduced dermal thickness and hydroxyproline content in bleomycin-induced murine dermal fibrosis and the tight skin 1 model, and additionally attenuated dermal fibrosis as well as fibrosis of the small intestine in a mouse model of sclerodermatous chronic graft versus host disease [42] .
Collectively, in vitro and in vivo data from model systems of tissue fibrosis demonstrated that application of sGC stimulators or activators uniformly attenuated ECM production and deposition -a hallmark of fibrosis -in various organs.
Inhibition of Cellular Proliferation
Effects of sGC modulators on cellular proliferation in fibrotic diseases can be studied either in in vitro proliferation assays using primary cells or cell lines or in situ by immunohistochemical detection of proliferating cells using specific antibodies against proliferation markers. The most commonly used cellular markers for proliferation are cell cycle-associated proteins such as Ki-67 and proliferating cell nuclear antigen (PCNA) [43] .
In vivo, treatment with the sGC stimulator BAY 41-2272 significantly reduced the number of PCNA-positive cells in the glomerulus of rats with anti-Thy1-induced mesangial proliferative glomerulonephritis, and double staining of PCNA with a CD90-specific antibody revealed that sGC stimulation in particular attenuated glomerular [28] . Similarly, in anti-Thy1-induced chronic glomerulosclerosis in uninephrectomized rats, BAY 41-2272 markedly reduced proliferation of glomerular as well as tubulointerstitial cells [31] . Proliferation of the latter was also significantly reduced by the sGC stimulator BAY 41-8543 as determined by PCNA immunohistochemistry in a rat model of renal recovery after relief of unilateral ureteral obstruction [32] .
BAY 41-8543 has additionally been shown to inhibit the proliferation of vascular smooth muscle cells induced by 5/6 nephrectomy in male but not female rats, as determined by PCNA-positive cell numbers per aortic media cross-section [29] . Consistently, in vitro BAY 41-2272 significantly reduced proliferation of primary vascular smooth muscle cells isolated from thoracic aortas of male rats [44] . sGC stimulators have also been shown to exert antiproliferative effects in PAH. While treatment with riociguat significantly inhibited the increase in PCNA-positive cells in the lung tissue of rats with hypoxia-and SU5416-induced severe angioproliferative PAH [36] , stimulation with BAY 41-2272 significantly inhibited proliferation of human primary pulmonary arterial smooth muscle cells in vitro, probably via induction of PAI-2 [45] .
Besides sGC stimulators, antiproliferative effects of the sGC activator cinaciguat have been investigated in cardiac fibroblasts. Cinaciguat significantly reduced basal proliferation of primary rat neonatal cardiac fibroblasts, as determined by cDNA synthesis measured by 3 H-thymidine incorporation, but in contrast to BAY 41-2272, it did not reduce fetal calf serum-stimulated DNA synthesis [46] . Cinaciguat was consistently less effective than BAY 41-2272 in inducing expression of PAI-2, the putative mediator of the antiproliferative effects, in human primary pulmonary arterial smooth muscle cells [45] .
Taken together, these findings indicate that the antiproliferative effect of cGMP enhancement by sGC modulators are more pronounced after sGC stimulation compared with activation.
Inhibition and Reversal of TGFβ-Induced Myofibroblast Differentiation
Besides enhanced proliferation and accumulation of excess ECM, fibrosis is characterized by the development and persistence of myofibroblasts. Myofibroblasts have a contractile phenotype and, in contrast to fibroblasts, express smooth muscle cell-specific proteins such as α-smooth muscle cell actin (SMA) or calponin (CNN), which therefore serve as myofibroblast markers [1, 3, 12] .
TGFβ1-induced myofibroblast differentiation of fibroblasts is mediated by elevated expression of nicotinamide adenine dinucleotide phosphate oxidase 4 and concomitant downregulation of antioxidant enzymes such as SOD2 [1, 3] . Moreover, myofibroblasts are characterized by enhanced expression and secretion of a variety of growth factors and cytokines including FGF, TGFβ, connective tissue growth factor, insulin-like growth factor (IGF) and modulators of the IGF signaling axis, e.g. IGFbinding protein 3 (IGFBP3) [1, 3, 12] .
sGC modulators have been shown to attenuate myofibroblast accumulation in various fibrosis models. Unilateral ureteral obstruction significantly increased the number of SMA-expressing tubulointerstitial cells in rat kidneys and the sGC stimulator BAY 41-8543 enhanced renal recovery after obstruction relief by reducing myofibroblast counts [32] . Similarly, BAY 41-2272 significantly decreased the number of SMA-stained cells in tissue sections from the left ventricle of rats with hypertension induced by suprarenal aortic constriction, and reduced SMA protein expression in cultured rat neonatal cardiac fibroblasts as determined by Western blotting [35] . In human cardiac fibroblasts, the sGC activator ataciguat suppressed the induction of SMA and connective tissue growth factor in response to TGFβ1 stimulation in vitro [27] . Moreover, ataciguat ameliorated the decrease in SOD2 protein expression in the noninfarcted left ventricle of rats with chronic heart failure after myocardial infarction [27] .
The sGC activator BAY 60-2770 significantly attenuated myofibroblast activation as determined by SMA immunohistochemistry and Western blotting in thioacetamide-induced hepatic fibrosis in rats [38] . In addition, BAY 60-2770 reduced SMA expression in advanced hepatic fibrosis and inhibited myofibroblast activation of hepatic stellate cells in vitro [38] . BAY 41-2272 reduced myofibroblast accumulation in injury-induced peritoneal fibrosis in eNOS-deficient mice, as determined by SMA gene expression [39] .
sGC stimulation by BAY 41-2272 or riociguat dosedependently reduced myofibroblast counts in murine dermal fibrosis induced by intradermal injection of bleomycin and in the tight skin 1 mouse model [40, 42] . Furthermore, sGC stimulation attenuated the numbers of SMA-expressing cells in a mouse model of dermal fibrosis induced by overexpression of constitutively active TGFβ receptor 1 and in a mouse model of sclerodermatous chronic graft versus host disease [41, 42] .
In vitro, sGC stimulation by BAY 41-2272 or sGC activation by BAY 60-2770 inhibited and reversed TGFβ1-induced fibroblast-to-myofibroblast differentiation of primary human dermal fibroblasts and primary human prostatic stromal cells, as determined by SMA, CNN1, and IGFBP3 mRNA and protein levels [41, 47] . Similarly, in pulmonary fibroblasts, the sGC activator cinaciguat in combination with PDE5 inhibition attenuated myofibroblast differentiation [48] .
Collectively, in vivo and in vitro data from fibrosis model systems demonstrate that sGC modulators inhibit myofibroblast activation and persistence in various organs. Inhibition of the activation of the primary effector cells of fibrosis appears to be a central mechanism of the observed antifibrotic properties of sGC stimulators and activators and is in line with data obtained after enhancement of the NO/cGMP signaling pathways by NO donors or PDE5 inhibitors [1, 3] .
Molecular Pathways Underlying Antifibrotic Effects of sGC Modulators
Most of the above-detailed antifibrotic effects of sGC modulators are descriptive and lack further investigation of the underlying molecular pathways. However, the fact that the antifibrotic activity of sGC modulators can be mimicked or enhanced by NO donors, PDE5 inhibitors or cell-permeable cGMP analogues, as well as inhibited by PKG inhibitors, strongly indicates that the effects are primarily mediated via elevation of cGMP [1, 47] .
PKG is a central downstream target of cGMP. Consistently, antiproliferative effects of cGMP on cardiac fibroblasts were mediated via PKG type I [49] . Similarly, PDE5 inhibition inhibited prostatic fibroblast proliferation as well as endothelin-1 or PDGF-induced cell migration of bladder myofibroblasts in a PKG-dependent way [50, 51] . While in vascular smooth muscle cells BAY 41-2272-induced inhibition of migration was restored by PKG inhibition, antiproliferative effects of the sGC stimulator appeared to be partially mediated via protein kinase A activation [44] .
In contrast to proliferation, the potential of PDE5 inhibition to block TGFβ-induced myofibroblast differentiation of prostatic stromal cells was unaffected by PKG inhibition. However, inhibition of the MAPK/ERK (extracellular signal-regulated kinase) pathway restored the capacity of TGFβ to induce differentiation in the presence of a PDE5 inhibitor [50] . Of note, in dermal fibroblasts, stimulation of sGC by BAY 41-2272 also interfered with TGFβ-dependent ERK signaling [41] . However, unlike inhibition of myofibroblast differentiation using PDE5 inhibitors, reversal of differentiation in prostatic stromal cells was neither affected by MAPK/ERK inhibition nor by PKG inhibition. In contrast, PDE5 inhibition in predifferentiated myofibroblasts resulted in an attenuation of PI3K/ AKT signaling. Consistently, PI3K or AKT inhibition mimicked the effects of cGMP enhancement and induced reversal of the cells to a fibroblast-like phenotype [14] .
Brain natriuretic peptide, an activator of membranebound guanylate cyclases (pGC), decreased collagen synthesis and increased matrix metalloproteinases via PKG signaling in cardiac fibroblasts [52] . Atrial natriuretic peptide, an activator of pGC, or a cGMP analog inhibited TGFβ-stimulated PAI-1 mRNA expression in cardiac fibroblasts, an effect that could be blocked by PKG inhibition [53] . Downstream of PKG, these effects appeared to be mediated via phosphorylation of Smad3 (at residues Ser309 and Thr388), thus preventing Smad3 nuclear translocation, suggesting a potential molecular mechanism that contributes to the antifibrotic effects of enhanced cGMP signaling [53] . Although pGC and sGC pathways seem highly compartmentalized in cells and tissues and might also be differentially regulated by PDEs, these results further support the broad antifibrotic potential of cGMP increase [54] .
However, the detailed molecular mechanisms underlying the association of aging and fibrosis still remain elusive. Of note, AGEs that accumulate during aging, timeand dose-dependently decreased NO production, cGMP synthesis and PKG activation in rat renal fibroblasts [6] . Taken together, the above-mentioned impaired capacity to induce the NFE2-related factor 2 antioxidant response in cells from aged mice [10] suggests that aging makes cells/tissues more susceptible to a persistent pro-oxidant shift in redox homeostasis that further attenuates NO/ cGMP signaling. Current knowledge on redox signaling and oxidative stress that promotes and perpetuates fibrosis in the context of aging has recently been reviewed elsewhere [11] . Future research will have to be performed to clarify the molecular alterations during aging and their relation to oxidative stress and inflammation, which are causative for higher risk of fibrotic diseases.
Conclusions
Fibrosis develops in response to tissue damage or inflammation via the action of growth factors secreted by activated platelets and infiltrating leukocytes, in particular TGFβ. Aging is considered a risk factor for fibrosis that likely promotes fibrogenesis via various mechanisms such as elevated oxidative stress, cellular senescence or 225 tion for fibrotic diseases that might at least slow disease progression. However, results from the ongoing clinical trials, e.g. in patients with systemic sclerosis, and future clinical studies are needed to prove the antifibrotic efficacy of these drugs.
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